In ovarian cancer, tumour specimens from patients with high-grade serous ovarian carcinoma and BRCA1 or BRCA2 loss (through germline or somatic mutations, or BRCA methylation) had significantly increased immune cell infiltrates [99] and overexpression of PD-L1 [100] compared to high-grade serous ovarian cancer specimens without BRCA mutations. This evidence concerns the gene BRCA1 and ovarian cancer.